Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma

靶向HMGB2可通过增强CD8+ T细胞功能和抑制肝细胞癌肿瘤生长发挥双重免疫调节作用。

阅读:3
作者:Wei-Feng Qu ,Gui-Qi Zhu,Rui Yang,Tian-Hao Chu,Zhi-Qi Guan,Run Huang ,Meng-Xin Tian,Xi-Fei Jiang,Chen-Yang Tao,Yuan Fang,Jun Gao,Xiao-Ling Wu,Jia-Feng Chen,Qian-Fu Zhao,Yi Wang,Yi-Chao Bu,Jian Zhou,Jia Fan,Wei-Ren Liu,Zheng Tang,Ying-Hong Shi

Abstract

T cell exhaustion is a critical obstacle for durable treatment response in hepatocellular carcinoma (HCC). Developing drugs that control tumor growth and simultaneously bolster immune function is of great significance. Although high-mobility group box 2 (HMGB2) has been reported to be crucial to HCC prognosis, its role in the tumor microenvironment remains unclear. Here, we found HMGB2+ CD8+ T cells as being associated with immune exhaustion and resistance to anti-PD-1 treatment through single-cell RNA sequencing. Mechanistically, HMGB2 impaired the oxidative phosphorylation in CD8+ T cells and inactivated the interferon-γ response in tumor cells, reducing the antitumor effector function. Tannic acid, a specific inhibitor of HMGB2, synergized with PD-1 antibody to attenuate tumor growth and reverse T cell exhaustion. Our findings highlight the unique role of HMGB2 as an immune exhaustion associated molecule. Targeting HMGB2 on both CD8+ T cells and tumor cells contributed to promising treatment strategies for HCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。